ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biologic drugs"

  • Abstract Number: 2584 • 2014 ACR/ARHP Annual Meeting

    Smoking Is Not Associated with Response to TNF Blockers in Patients with Axial Spondyloarthritis

    Anna Dellyes1, Pierre Lafforgue1, Vincent Pradel2 and Thao Pham1, 1Rheumatology, APHM, Aix Marseille University, Marseille, France, 2Epidemiology, APHM, Aix Marseille University, Marseille, France

    Background/Purpose Smoking has been reported as associated with increase disease activity, more functional impairment, poorer quality of life and more radiographic damages in patients (pts)…
  • Abstract Number: 1522 • 2014 ACR/ARHP Annual Meeting

    Impact of Sarilumab on Health Related Quality of Life (HRQoL),  Fatigue, and Sleep in Rheumatoid Arthritis Patients at Week 24 – Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study

    Vibeke Strand1, George Joseph2, Hubert van Hoogstraten2, Chieh-I Chen3, Chungpeng Fan2, Paulo Carita4, Neil Graham3, Tanya Momtahen2 and Mark C Genovese5, 1Biopharmaceutical Consultant, Portola Valley, CA, 2Sanofi, Bridgewater, NJ, 3Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 4Sanofi, Chilly-Mazarin, France, 5Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA

    Background/Purpose: Sarilumab, a fully human monoclonal antibody directed against the IL-6 receptor, demonstrated efficacy in the phase 3 part of the RA-MOBILITY study (NCT01061736) in…
  • Abstract Number: 2559 • 2014 ACR/ARHP Annual Meeting

    Vitamin D insufficiency  and Deficiency in Two European Cohorts of Patients with Inflammatory Rheumatic Disorders

    Alessandra Vacca1, Giovanni Porru1, Grazia Dessole1, Alessandro Mathieu1, Catherine Cormier2, Yvonne Fulla2, Andre Kahan2 and Yannick Allanore3, 1Unit and Chair of Rheumatology, University Hospital of Cagliari, Cagliari, Italy, 2Rheumatology A Department, Cochin Hospital, APHP, Paris Descartes University, Paris, France, 3Paris Descartes University, Rheumatology A Department and INSERM U1016, Cochin Hospital, Paris, France

    Background/Purpose Vitamin D plays an important role in the modulation of immune system and epidemiologic data indicate low vitamin D levels in autoimmune diseases such…
  • Abstract Number: 1486 • 2014 ACR/ARHP Annual Meeting

    Rapid Onset of Clinical Benefit Is Associated with a Reduction in Validated Biomarkers of Disease in Patients with Rheumatoid Arthritis Treated with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFRá

    Iain B. McInnes1, Gerd Burmester2, Joel M. Kremer3, Pedro Miranda4, Mariusz Korkosz5, Jiri Vencovsky6, Andrea Rubbert-Roth7, Eduardo Mysler8, David Close9, Matthew A. Sleeman10, Alex Godwood11, Sara Sandbach12, Patricia C. Ryan13, Dominic Sinibaldi14, Wendy White13, Nadine A. Defranoux15 and Michael Weinblatt16, 1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, 3Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, 4Centro de Estudios Reumatologicos, Santiago, Chile, 5Inernal Medicine and Gerontology, Malopolskie Centrum Medyczne, Krakow, Poland, 6Rheumatology, Charles University Institute of Rheumatology, Prague, Czech Republic, 7Med Clinic I, University of Cologne, koln, Germany, 8Rheumatology, OMI, Buenos Aires, Argentina, 9Clinical Development, MedImmune Ltd, Cambridge, United Kingdom, 10Respiratory, Inflammation and Autoimmunity, MedImmune Ltd, Cambridge, United Kingdom, 11Clinical Biostatics and Data Management, MedImmune Ltd, Cambridge, United Kingdom, 12Clinical biologics, MedImmune Ltd, Cambridge, United Kingdom, 13Translational Sciences, MedImmune, Gaithersburg, MD, 14R&D IS Translational & Clinical Informatics, MedImmune, Gaithersburg, MD, 15Crescendo Bioscience Inc., South San Francisco, CA, 16Rheumatology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose Macrophages are pivotal to rheumatoid pathogenesis and their inflammatory products drive many of the signs and symptoms of disease. Mavrilimumab inhibits macrophage activation and…
  • Abstract Number: 2482 • 2014 ACR/ARHP Annual Meeting

    Use of Biologic Therapy As Monotherapy in Patients with Rheumatoid Arthritis

    Antonio Gómez-Centeno1, Olga Martínez2, Francisco Javier Ballina3, José Manuel Rodríguez4, Jenaro Graña5, Manuel Brito6, Juana Sampedro7, Gerardo Iglesias8, Concepción Delgado9 and Indalecio Monteagudo10, 1Hospital Parc Taulí, Sabadell, Spain, 2Hospital Virgen de la Concha, Zamora, Spain, 3Hospital Central de Asturias, Oviedo, Spain, 4Hospital Getafe, Getafe, Spain, 5Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, 6Hospital Nuestra Señora Candelaria, Santa Cruz de Tenerife, Spain, 7Hospital Virgen de la Salud, Toledo, Spain, 8Complejo Hospitalario Palencia, Palencia, Spain, 9Hospital Clínico Lozano Blesa, Zaragoza, Spain, 10Hospital Gregorio Marañón, Madrid, Spain

    Background/Purpose The treatment for Rheumatoid Arthritis (RA) is based on synthetic or biological disease-modifying drugs (DMARDs). Current guidelines recommend biologics in combination with methotrexate as…
  • Abstract Number: 1432 • 2014 ACR/ARHP Annual Meeting

    Mortality Ratio of Rheumatoid Arthritis Under Biological Treatment

    Umut Kalyoncu1, Abdulsamet Erden2, Hakan Babaoglu3, Murat Torgutalp3, Sadettin Kilickap4, Omer Karadag5, Sule Apras Bilgen5, Ihsan Ertenli1, Ali Akdogan5 and Sedat Kiraz5, 1Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey, 2Rheumatology,Hacettepe University Faculty of Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey, 3Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey, 4Preventive Oncology, Hacettepe University, Faculty of Medicine, Ankara, Turkey, 5Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey

    Mortality Ratio of Rheumatoid Arthritis Under Biological Treatment: HUR-BIO real life results.Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease, which, in many patients, leads…
  • Abstract Number: 2423 • 2014 ACR/ARHP Annual Meeting

    Prevalence of Subclinical Synovitis Detected By Ultrasound in Rheumatoid Arthritis and Psoriatic Arthritis Patients Receiving Anti-TNF-α Therapy with Extended Interval of Administration

    José M. Senabre-Gallego1, José Rosas-Gómez de Salazar1, Esteban Salas-Heredia1, Gregorio Santos-Soler1, Francisca Llinares-Tello2, Carlos Santos-Ramirez3, Mabel Sánchez-Barrioluengo4, Xavier Barber-Vallés5, Rafaela Ortega3, Ana Pons1, Catalina Cano1 and Maria Luisa Lorente-Betoret1, 1Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, 2Laboratory, Hospital Marina Baixa, Villajoyosa, Spain, 3Rheumatology, Hospital Marina Salud, Denia, Spain, 4Ingenio (CSIC-UPV), Universitat Politècnica de València, Valencia, Spain, 5Center of Operations Research, University Miguel Hernández, Elche, Spain

    Background/Purpose To estimate the prevalence of subclinical synovitis detected by ultrasound in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients in clinical remission receiving anti-TNFα…
  • Abstract Number: 1251 • 2014 ACR/ARHP Annual Meeting

    Efficacy of Certolizumab in Patients with Refractory Uveitis to Other Biologic Therapy. Study of 7 Cases

    Montserrat Santos-Gómez1, Victor Llorens2, Marina Mesquida2, Ricardo Blanco1, Vanesa Calvo-Río1, Olga Maíz3, Ana Blanco4, Maite Sainz de la Maza2, Alfredo Adan2, Leyre Riancho-Zarrabeitia1 and Miguel A. González-Gay1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, 2Ophthalmology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 3Rheumatology, Hospital Universitario de Donostia. San Sebastián. Spain, San Sebastián, Spain, 4Ophthalmology, Hospital Universitario de Donostia. San Sebastián. Spain, San Sebastián, Spain

    Background/Purpose Anti-TNF-α therapy may be useful in cases of uveitis refractory to standard synthetic immunosuppressive drugs. Infliximab (IFX) and adalimumab (ADA) are the biologic agents…
  • Abstract Number: 2407 • 2014 ACR/ARHP Annual Meeting

    Early Treatment in Rheumatoid Arthritis and Its Effect on Patient Outcomes

    Laurent Chanroux and Joan Casellas, Therapy Watch, The Research Partnership, London, United Kingdom

    Background/Purpose: It is generally thought that the early treatment of patients with rheumatoid arthritis (RA) leads to improved patient outcomes over time. Our study aims…
  • Abstract Number: 1164 • 2014 ACR/ARHP Annual Meeting

    Inequity: Level of Education Is Associated with Access to Biologic Dmards Even in a Country with Highly Developed Social Welfare (Norway)

    Polina Putrik1, Sofia Ramiro2, Elisabeth Lie3, Andras Keszei4, Desirée van der Heijde5, Robert Landewé6, Tore K. Kvien7, Till Uhlig7 and Annelies Boonen8, 1Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 2Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam & Hospital Garcia de Orta, Almada, Portugal, Amsterdam, Netherlands, 3Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Medical Informatics, Uniklinik RWTH Aachen University, Aachen, Germany, 5Leiden University Medical Center, Leiden, Netherlands, 6Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 7Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 8Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands

    Background/Purpose Biologic DMARDs (bDMARDs) have greatly improved the outcome of rheumatoid arthritis (RA). Investigating possible inequities in access to bDMARDs across socio-economic factors is important,…
  • Abstract Number: 2380 • 2014 ACR/ARHP Annual Meeting

    Durability of First Biologic Is Not Influenced By Initial/Early DAS28

    Gina Rohekar1, Binu Jacob2, Janet E. Pope3 and Claire Bombardier4, 1Rheumatology, St. Joseph's Hospital, London, ON, Canada, 2University Health Network, Toronto General Research Institute, Toronto, ON, Canada, 3Medicine, Western University, London, ON, Canada, 4Rheumatology, University of Toronto, Toronto, ON, Canada

    Background/Purpose:   The Ontario Best Practices Research Initiative (OBRI) collects data on RA treatment in a real-world setting.  Patients are enrolled and prospectively followed to…
  • Abstract Number: 1144 • 2014 ACR/ARHP Annual Meeting

    Economic Implications for Policies Regarding Triple Therapy Use in Patients with Rheumatoid Arthritis

    Nick Bansback1, Diane V. Lacaille2, Daphne Guh3, Kamran Shojania4 and Aslam H. Anis3, 1School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, 2Rheumatology, Arthritis Research Centre of Canada/University of British Columbia, Richmond, BC, Canada, 3St. Paul's Hospital, Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, 4Rheumatology, University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Recent randomized controlled trials in rheumatoid arthritis (RA) patients have determined that a strategy of first adding the two Disease Modifying Anti-Rheumatic Drugs (DMARDs)…
  • Abstract Number: 2202 • 2014 ACR/ARHP Annual Meeting

    Pilot Study of Tocilizumab in Patients with Erdheim-Chester Disease

    Giulio Cavalli1, Alvise Berti1, Barbara Gulgielmi1, Marco Gelpi2, Riccardo Biavasco2, Corrado Campochiaro1, Alessandro Tomelleri2, Marina Ferrarini3, Maria Grazia Sabbadini2 and Lorenzo Dagna2, 1Internal Medicine and Clinical Immunology, Vita-Salute San Raffaele University, Milan, Italy, 2Vita-Salute San Raffaele University, Milan, Italy, 3Department of Oncology, San Raffaele Scientific Institute, MIlan, Italy

    Background/Purpose Erdheim-Chester disease (ECD) is a rare, systemic disorder of unknown etiology, characterized by tissue infiltration with CD68+, CD1a- foamy histiocytes. ECD is a chronic,…
  • Abstract Number: 1001 • 2014 ACR/ARHP Annual Meeting

    Fibroblast-like Synoviocytes Inhibit Wnt Signaling Pathway By Secreting Dockcop-1

    Satoshi Yamasaki and Eiji Sugiyama, Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan

    Background/Purpose: There is evidence of osteoclast activation in the inflamed joints of patients with rheumatoid arthritis (RA). Studies that focus on osteoblasts are not sufficient…
  • Abstract Number: 2133 • 2014 ACR/ARHP Annual Meeting

    Efficacy of Tocilizumab Therapy in Patients with Rheumatoid Arthritis Based on FDG-PET/CT

    Koichi Okamura1, Yukio Yonemoto1, Chisa Okura2 and Kenji Takagishi1, 1Orthopaedic Surgery, Gunma University, Maebashi, Japan, 2Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan

    Background/Purpose: A humanized anti-interleukin-6 receptor (anti-IL-6R) antibody, tocilizumab (TCZ), is one of the biologics and the C-reactive protein (CRP) level and erythrocyte sedimentation rate (ESR)…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology